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Background: Many people with COPD report difficulties falling asleep or staying asleep, 
insufficient sleep duration, or nonrestorative sleep. Cognitive behavioral therapy for insomnia 
(CBT-I) has proved effective not only in people with primary insomnia but also in people with 
insomnia comorbid with psychiatric and medical illness (eg, depression, cancer, and chronic 
pain). However, CBT-I has rarely been tested in those with COPD who have disease-related 
features that interfere with sleep and may lessen the effectiveness of such therapies. The purpose 
of this study was to determine the feasibility of applying a CBT-I intervention for people with 
COPD and to assess the impact of CBT-I on insomnia severity and sleep-related outcomes, 
fatigue, mood, and daytime functioning.
Methods: The study had two phases. In Phase 1, a 6-weekly session CBT-I intervention protocol 
in participants with COPD was assessed to examine feasibility and acceptability. Phase 2 was 
a small trial utilizing a prospective two-group pre- and post-test design with random assign-
ment to the six-session CBT-I or a six-session wellness education (WE) program to determine 
the effects of each intervention, with both interventions being provided by a nurse behavioral 
sleep medicine specialist.
Results: Fourteen participants (five in Phase 1 and nine in Phase 2) completed six sessions 
of CBT-I and nine participants completed six sessions of WE. Participants indicated that both 
interventions were acceptable. Significant positive treatment-related effects of the CBT-I inter-
vention were noted for insomnia severity (P = 0.000), global sleep quality (P = 0.002), wake 
after sleep onset (P = 0.03), sleep efficiency (P = 0.02), fatigue (P = 0.005), and beliefs and 
attitudes about sleep (P = 0.000). Significant positive effects were noted for depressed mood 
after WE (P = 0.005).
Conclusion: Results suggest that using CBT-I in COPD is feasible and the outcomes compare 
favorably with those obtained in older adults with insomnia in the context of other chronic 
illnesses.
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Introduction
It is estimated that up to 50% of people with COPD report difficulty falling asleep, 
staying asleep, or unrefreshing sleep (ie, insomnia).1,2 This high prevalence rate of 
insomnia, nearly double that found in the population at large, may be due to several 
factors including nocturnal dyspnea, diminished physical activity, reduced time spent 
outside and/or reduced exposure to bright light, and/or the expansion of sleep oppor-
tunity as a means of coping with disease-related fatigue. The combination of these 
factors suggests that insomnia in the context of COPD may be responsive to cognitive 
behavioral therapy for insomnia (CBT-I). Evaluating the efficacy of this approach is International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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additionally important in view of the natural tendency of 
clinicians to avoid using hypnotics in COPD patients (as they 
may cause respiratory depression and a decreased arousal 
response to hypercapnia).3
CBT-I is a nonpharmacological therapy, which is pro-
vided over several sessions and commonly includes stimulus 
control, sleep restriction, sleep hygiene, training in relaxation, 
and cognitive therapy (see Table 1). To date, CBT-I has been 
exhaustively evaluated in patients with primary insomnia. In 
this context, CBT-I was found to be as efficacious as pharma-
cotherapy during acute treatment and yielded more durable 
benefits following treatment.4–11 That is, the clinical gains of 
CBT-I are, unlike those of pharmacotherapy, sustained once 
treatment has ceased.
In recent years, a variety of studies have assessed the 
efficacy of CBT-I for insomnia comorbid with psychiatric 
and medical illness.12,13 These studies have shown CBT-I to 
be effective for the insomnia that co-occurs with a variety of 
illnesses including depression,14 osteoarthritis,15 cancer,16,17 
fibromyalgia,18 chronic pain,19–21 cardiopulmonary disease,22 
and sleep disordered breathing.23   Remarkably, the pre- 
to post-treatment effect sizes are, more often than not, 
comparable with those for primary insomnia and in some 
cases larger. Finally, there is growing evidence that 
improved sleep following CBT-I influenced the clinical 
course of the comorbid illnesses. The data in this regard 
are preliminary but nonetheless suggestive, as CBT-I has 
been shown to result in higher response and remission rates 
when used as an adjuvant treatment with antidepressant 
therapy24 and to increase pain tolerance in patients with 
chronic pain.20
Several factors suggest a clear need to evaluate the effects 
of CBT-I in the context of COPD. Behavioral factors may, in 
part, be responsible for the occurrence of chronic   insomnia 
with COPD. Many physicians are reluctant to prescribe 
hypnotics to patients with COPD and, in both primary 
(insomnia disorder) and secondary insomnia (comorbid 
insomnia), CBT-I has demonstrated efficacy. Therefore, the 
purposes of this study were to determine the feasibility of 
applying a CBT-I intervention for people with mild to severe 
COPD manifestations and to assess the effects of CBT-I on 
insomnia severity, sleep-related outcomes (self-reported and 
actigraphic sleep quality indicators, sleep beliefs/attitudes), 
fatigue, mood, and daytime functioning.
Methods
Design
This preliminary study was conducted in two phases. In 
Phase 1, a 6-weekly session CBT-I intervention protocol 
was tested with five participants with COPD to examine 
feasibility and acceptability of the CBT-I intervention. An 
audiotaped interview was conducted with each participant at 
the end of the six-session intervention to explore perceptions 
about the length and components of the CBT-I intervention 
and participants’ rating of acceptability to the intervention. 
Phase 2 was structured as a small trial, utilizing a prospective 
two-group pre- and post-test design with stratified random 
assignment of 18 participants to the six-session CBT-I or a six-
session wellness education (WE) program. Randomization 
was stratified by COPD disease severity and gender.
setting and sample
The research was approved by the local institutional review 
board and all participants provided written consent to 
  participate. Participants with mild to severe COPD25 and no 
other major health problems were recruited from the Chicago 
area through print advertisements and word of mouth. The 
inclusion criteria were: abnormal FEV1/FVC ratio ,70%, 
age $45 years, stable clinical condition (no major exacerba-
tion of COPD within the previous month) and self-reported 
difficulty initiating or maintaining sleep, waking up too early 
or poor quality sleep. Participants were excluded if they showed 
evidence of restrictive lung disease, history of asthma, a major 
sleep disorder other than insomnia (sleep apnea or periodic limb 
movements), hypnotic medication use, resting   hypoxemia, the 
presence of a potentially debilitating disease such as cancer, 
congestive heart failure, kidney disease, liver failure or cir-
rhosis, a self-reported current diagnosis of major depression, 
or currently participating in pulmonary rehabilitation.
Table 1 Description of the CBT-I protocol
session 1 T provides CBT-I overview. P completes daily sleep diary
session 2 T and P discuss sleep diary/actigraphy data, stimulus 
control, and sleep restriction behaviors with bedtime 
and arise time chosen based on sleep diary data and 
sleep restriction homework
session 3 T and P discuss sleep diary/actigraphy, any problems 
with homework, adjustments in sleep prescription, and 
sleep hygiene measures
session 4 T and P discuss sleep diary/actigraphy data, adjustments 
to sleep prescription, sleep medications, and cognitive 
techniques for managing everyday and sleep-loss worries
session 5 T and P discuss sleep diary/actigraphy data, adjustments to 
sleep prescription, and how to engage in two relaxation 
techniques (imagery, progressive muscle relaxation)
session 6 T and P review progress and discuss ongoing techniques 
to prevent insomnia relapse
Abbreviations:  CBT-I,  cognitive  behavioral  therapy  for  insomnia;  T,  therapist; 
P, participant.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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screening and sample
The initial screening was by telephone followed by a first 
screening visit to the authors’ pulmonary research lab and 
a second screening visit for an overnight polysomnography. 
During the first screening visit, participants were assessed 
for COPD disease severity using pulmonary function testing. 
Two instruments were administered: the Sleep Impairment 
Index26 to assess for inclusion and the Hospital Anxiety and 
Depression Scale (HADS)27 criteria to assess for exclusion. 
At the second screening visit participants were screened 
for significant sleep apnea and periodic limb movements 
during sleep.
Instruments
Assessment
Participants were assessed for COPD disease severity using 
pulmonary function testing, which was performed on the 
VMAX Encore 22 (Viasys Healthcare, Inc, Yorba Linda, 
CA) according to established standards.28
The Sleep Impairment Index (SII),26,29 also known as 
the Insomnia Severity Index, was administered to select 
participants with at least a moderate perception of insomnia. 
The index includes seven items, each rated on a five-point 
scale (0 = not at all, 4 = extremely) to evaluate: (1) sleep 
onset severity, (2) sleep maintenance, (3) early morning 
awakening problems, (4) satisfaction with current sleep 
pattern, (5) interference with daily functioning, (6) impair-
ment attributed to the sleep problem, and (7) level of distress 
caused by the sleep problem. Participants scoring ,10 were 
excluded from the study.29
HADS,27,30 with a cutoff score of eleven for the depression 
scale, was used to screen for depressive symptoms; this scale 
includes 14 items rated on a four-point Likert scale.
The Epworth Sleepiness Scale was used to measure the 
severity of daytime sleepiness. Respondents rated eight items 
regarding the likelihood of dozing in sedentary situations on 
a scale from 0 (never) to 3 (high chance).
Participants were screened for major sleep disorder using 
a one-night polysomnography (PSG) with pulse oximetry 
to rule out sleep-related breathing and movement disorders 
associated with arousals. A standard PSG montage, including 
electroencephalographic, electromyographic, electrooculo-
graphic, electrocardiographic, respiratory, and limb move-
ment monitoring, was used. Sleep stages were scored by an 
experienced technician according to standardized   criteria.31 
People with an apnea/hypopnea index of .10, and those 
with .10 periodic limb movements associated with arousal 
per hour of sleep were excluded. The PSG montage included 
pulse oximetry – used to exclude participants with hemoglo-
bin saturation #85% for more than 5 minutes during sleep.
Outcome
The CBT-I intervention was assessed for feasibility using an 
interview and questionnaire. Participants were asked about 
their reactions to the length and components of the CBT-I 
intervention in an audiotaped interview. The eight-item 
Insomnia Treatment Acceptability Scale (ITAS),26 modified, 
was used to examine treatment acceptability. Respondents 
scored each item from 0 (not at all acceptable) to 4 (very 
acceptable) to rate if the rationale made sense, how acceptable 
the treatment was for them, suitability for their sleep problem, 
and expected effectiveness for their sleep problem. For the 
study sample, Cronbach’s alpha for the ITAS was 0.85.
The Sleep Impairment Index26,29 was used to measure 
insomnia severity. Total scores range from 0 to 28, with high 
scores indicating greater insomnia severity. For the study 
sample, the Cronbach’s alpha coefficient was 0.86.
Perceived sleep quality was measured using the Pittsburgh 
Sleep Quality Index (PSQI) and a sleep diary.26 PSQI32,33 is 
a 24-item instrument that measures perceived sleep quality 
with a global sleep quality index (the sum of seven component 
scores). Higher scores indicate poorer sleep quality. For the 
study sample, the PSQI Cronbach’s alpha was 0.76.
Participants also completed a daily sleep diary26 through-
out the study from which several sleep quality indicators 
were derived. These included sleep latency, minutes to fall 
asleep, frequency and duration of awakenings after sleep 
onset (WASO), time in bed trying to sleep, and total sleep 
time (TST). Sleep efficiency (SE) was computed as the ratio 
of total sleep time to time spent in bed and multiplied by 100. 
Sleep variables were scored for each night and a weekly mean 
was computed.34,35
Actigraphic sleep quality indicators were assessed 
using the AW-2 Actiwatch (Minimitter, Philips Respironics, 
Andover, MA). It was programmed for start time and data 
collection interval and data were retrieved for analysis via a 
personal computer interface using scoring software provided 
with the accelerometer. The accelerometer was worn at night 
on the nondominant wrist for a minimum of 3 days at baseline 
and again at the end of the intervention and the report was 
reviewed at each session. Scores for the same variables as 
from the sleep diary were derived.36
Sleep-related beliefs and attitudes were measured using 
the Dysfunctional Beliefs and Attitudes about Sleep Scale. 
The scale consists of 30 items that measure sleep-related 
beliefs or attitudes in five themes: (1) misattributions International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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or amplification of the consequences of insomnia, (2) 
  diminished perception of control and predictability of sleep, 
(3) unrealistic sleep expectations, (4) misconceptions about 
the causes of insomnia, and (5) faulty beliefs about sleep-
promoting practices. It includes a 0–10 Likert scale ranging 
from “strongly disagree” to “strongly agree.” Higher scores 
indicate more dysfunctional beliefs.37,38 For the study sample, 
Cronbach’s alpha coefficient was 0.86.
Fatigue was measured using two instruments. The four-
item Chronic Respiratory Disease Questionnaire Fatigue 
Scale (CRQ-F),39–41 was used to measure the frequency and 
intensity of fatigue. The total score was derived from a mean 
of the four items, each scored on a seven-point scale. Lower 
scores indicated more fatigue. A change of at least 0.5 per 
item was considered the minimum for clinical significance 
and a change of one per item was considered of moderate 
clinical significance.42 For the study sample, Chronbach’s 
alpha coefficient was 0.91. The seven-item fatigue-inertia 
subscale of the Profile of Mood States (POMS-F) was 
also used to measure fatigue.43,44 For the study sample, the 
  Cronbach’s alpha coefficient for the POMS-F was 0.89.
Anxious and depressed moods were assessed using 
the tension-anxiety (POMS-A) and depression-dejection 
(POMS-D) subscales of the POMS.43 For the study sample, 
Cronbach’s alpha coefficients for the POMS-A and the 
POMS-D were 0.86 and 0.92, respectively.
Perceived daytime function was measured by the Func-
tional Performance Inventory (FPI).45,46 The FPI is a 65-item 
instrument that measures performance of day-to-day   activities. 
Six subscales include body care, maintaining the house-
hold, physical exercise, recreation, spiritual activities, and 
social interaction. The FPI potential total score range is 0–3, 
with higher scores reflecting better daytime functioning. The 
Cronbach’s alpha for the FPI was 0.97 in this study.
Procedures (intervention and control 
condition)
The CBT-I intervention protocol followed Perlis and col-
leagues’ insomnia treatment protocol, with modifications 
to the sleep restriction and cognitive therapy components 
(described below).47 Sessions were provided by a nurse behav-
ioral sleep medicine specialist. Behavioral sleep medicine 
training included coursework in cognitive behavioral inter-
vention, attending a 2.5-day seminar on insomnia and CBT-I, 
observing cases where CBT-I was delivered by a licensed 
clinical psychologist, and delivering CBT-I under supervision 
of a physician board certified in sleep medicine. Consulta-
tions with a licensed clinical psychologist   experienced in 
CBT-I were obtained as needed during the training period. 
Intervention sessions were audiotaped and sent to a licensed 
clinical psychologist experienced in CBT-I who assessed the 
sessions for fidelity.
Early on, it was recognized that CBT-I participants ben-
efited from seeing the actigraphy report during their session 
and found it worthwhile to wear the device at night during the 
intervention period. During each session, the actigraphy and 
the sleep diary data were reviewed and time to bed and out 
of bed were discussed to score the actigraphy, provide feed-
back, and encourage participants to adhere to “homework” 
and completing the sleep diary. Thus, each session included 
a review of the sleep diary and actigraphy data, a didactic/
interactive presentation and discussion to answer questions, 
and work on problems encountered while implementing the 
study homework in the previous week.
In session 1, the study components were described and 
the Spielman model of insomnia was discussed.48 The main 
components of the intervention, stimulus control and sleep 
restriction, were introduced during session 2. Information on 
ways to optimize sleep was given. For instance, participants 
were advised to get out of bed if awake longer than 15 minutes 
and go into another room (to reinforce the relationship 
between bed and sleep), returning to bed when they again felt 
sleepy. Discussion also centered around bedtimes and rising 
times and participants were recommended to limit their time 
in bed to the amount of time they were sleeping, according 
to their sleep diary, to consolidate their sleep, but not less 
than 5 hours per night. The prescribed “time to bed” for the 
next week was set at each session by setting time in bed to an 
amount approximately equal to average sleep ability (average 
TST as assessed by the sleep diary), where “lights off” was 
determined by subtracting the average TST from the desired 
wakeup (time out of bed) time. In general, the recommended 
bedtime was moved earlier weekly by 15–30 minutes, the 
amount of time determined by agreement of the therapist and 
participant, if there was an improvement in sleep efficiency, 
defined as $85% sleep efficiency. Bedtime was kept the 
same if sleep efficiency was between 80%–84% and delayed 
if #79%. This differs from the sleep restriction procedure 
described in Perlis et al in which the time is moved earlier 
by 15 minutes without variation.47
Adherence to stimulus control and sleep restriction was 
assessed at each session using the sleep diary and/or the 
actigraph. Evaluation of adherence to stimulus control was 
assessed by examining responses to a sleep diary question, 
which asked how the participant managed periods awake 
during the night. Evaluation of adherence to sleep restriction International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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was assessed by comparing the recommended time in bed 
with the reported time in bed.
The remainder of each session included a didactic/ 
interactive presentation of a new topic followed by   discussion. 
Topics included sleep hygiene, including information about 
the effect of temperature and light (session 3); information 
about medications for sleep (session 4); a cognitive compo-
nent focusing on worry and stress, including ways to work 
through worries49 (note: this component differs from the 
procedure described in Perlis et al47). Because people with 
COPD struggle with anxiety and worries,50 in addition to 
cognitive therapy on reducing catastrophic thoughts about 
sleep, work also focused on strategies to manage everyday 
worries and relaxation techniques (session 5), and a review 
and discussion of relapse prevention (session 6).
WE sessions were focused on topics related to COPD. 
Each session was conducted by the same nurse behavioral 
sleep medicine specialist who provided the CBT-I program. 
Topics included how the lungs work, medications com-
monly prescribed for people with COPD, inhalers and other 
breathing equipment, breathing techniques, managing a 
cold or flu and vaccination information, and environmental 
influences.
Analysis
The feasibility interview data were transcribed from the 
audiotapes, and the qualitative data were analyzed using 
inductive methods for content analysis. Quantitative data 
were analyzed with descriptive statistics and paired t-tests 
using PASW Statistics 18 (v 18.0.0; SPSS, Inc, Chicago, IL). 
Item missing values were replaced using mean substitution. 
For unit missing data, it was determined whether missing 
data were missing completely at random. Missing data 
occurred randomly except in one subject in the CBT-I group 
where complete sleep diary data were missing. Bivariate 
relationships were examined with Pearson’s correlations. 
Analysis of variance (ANOVA) was used to compare baseline 
characteristics for the groups in terms of age, gender, and 
pulmonary function tests. Difference scores between pre- and 
postintervention were used to calculate Cohen’s d within 
effect size as: mean score difference pre- to post-divided by 
the pooled standard deviation (SD). Phase 1 and 2 CBT-I 
data were combined for selected analyses as described in 
the Results section.
Results
A total of 90 potential participants completed the initial 
telephone screening and 50 people were excluded at the first 
laboratory screening visit. Twenty-four people were found to 
be eligible, 14 completed six sessions of CBT-I and nine com-
pleted six sessions of WE. One participant was lost before 
baseline as they were unable to be contacted. Figure 1 shows 
a flow diagram of the study enrollment.
Table 2 describes baseline characteristics for partici-
pants who completed the study. No significant differences 
were noted between groups in the baseline characteristics, 
including for nighttime apnea/hypopnea index, periodic limb 
movement arousal index, SaO2, or for excessive daytime 
sleepiness. Participants had mild to moderate COPD accord-
ing to the Global initiative for chronic Obstructive Lung 
Disease (GOLD) standard;51 GOLD stage I (n = 4), GOLD 
stage II (n = 12), and GOLD stage III (n = 7).
CBT-I feasibility
Acceptable feasibility was judged by intervention participa-
tion and self-measurement rates; reports on the ITAS and for 
the subset who were interviewed on audiotape.
Participants in Phase 1 (n = 5) who completed the audio-
taped interview at the end of the study verbalized that the 
CBT-I program helped them achieve more and better sleep. 
In general they agreed with the average 1-hour length of the 
sessions but 2/5 participants indicated that they would have 
liked more sessions; one indicated that six sessions was about 
right and one person suggested that the program be offered 
online. Participants indicated that their family members were 
supportive of their CBT-I activities. Selected comments from 
participants in the CBT-I:
•	 “I got sleep. I got sleep. I slept. I was able to sleep.”
•	 “I’m kind of surprised that it helped but it did.”
•	 “I think just learning that it’s actually part of things 
that I can control rather than saying that it is just you 
know, part of nature, part of the aging process. There 
were actually things that I could control to help me get 
a better night’s sleep.”
All participants in Phase 2 were willing to be random-
ized to either intervention. There were no dropouts from the 
study after baseline occurred and no sessions were missed, 
although some were rescheduled due to holidays, weather, 
and personal reasons. One participant experienced symptoms 
of an acute exacerbation of COPD and was treated by his phy-
sician between CBT-I sessions. This participant took part in 
the weekly CBT-I sessions without interruption.   Twenty-two 
people completed the sleep diary on paper, mostly due to 
lack of computer access or computer literacy, and one person 
completed the online version of the identical sleep diary. One 
participant refused to complete the sleep diary during the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Phone screening for eligibility
90
Excluded
Did not meet PFT inclusion criteria
Refused to participate
Other reasons
50
Excluded by PSG
16a
PLM with
arousals >
10/h
5
AHI > 10 
11
Completed CBT-I
9
Dropped out
0
Completed 6
sessions of CBT-I
(Phases 1 and 2)
14
Phase 1
Completed CBT-I
5
SaO2 < 85%
for ≥ 5 min
3
Phase 2
Randomized
18
Completed WE
9
Completed six
sessions of WE
(Phase 2)
9
Dropped after enrollment 
but before baseline
1
Figure 1 Flow diagram of the study enrollment. 
Note: aThree participants were excluded by more than one criterion. 
Abbreviations: AhI, apnea/hypopnea index; CBT-I, cognitive behavioral therapy for insomnia; PFT, pulmonary function testing; PLM, periodic limb movement; Psg, 
programmable sound generator; We, wellness education.
intervention period but wore the actigraph at night throughout 
the study and participated in all sessions.
All participants in Phases 1 and 2 (n = 14) reported that 
the CBT-I intervention was acceptable on the ITAS (range 
0–4; mean [M] = 3.1, SD = 0.6). The WE group also reported 
that their intervention was acceptable but acceptance was 
somewhat lower and more variable (M = 2.7, SD = 0.8; see 
Figure 2). Subjects in the WE group had lower mean scores 
(range 0–4) compared with the CBT-I group on the item mea-
suring expectation for how effective the treatment would be 
in the short term (M = 2.2, SD = 1, vs M = 3.1, SD = 0.7).
CBT-I outcomes
Descriptive statistics and pre- and postintervention outcomes 
for the sleep-related measures are presented in Table 3. 
  Participants reported moderate levels of insomnia at baseline. 
In general when compared with the CBT-I group, participants 
in the WE group reported better sleep preintervention but 
had worse preintervention sleep on actigraphy. Correlations 
between sleep diary and actigraphy variables at baseline were 
moderate to low for sleep latency, wake after sleep onset, 
total sleep time, and sleep efficiency (r = 0.66, 0.18, 0.28, 
and 0.13 respectively).
For the CBT-I group (n = 14), significant within-group 
differences were noted for insomnia severity (P = 0.000), 
PSQI global sleep quality (P = 0.002), sleep diary WASO 
(P = 0.030), sleep diary SE (P = 0.017), actiwatch SE 
(P = 0.028), and dysfunctional beliefs and attitudes about 
sleep (P = 0.000). No significant within-group differences 
in subjectively or objectively measured sleep indicators were 
seen pre- or post-WE. All other sleep diary and actigraphic 
variables showed mean changes in an improved direction International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 sample characteristics at baseline
Characteristics All subjects (n = 23)a 
Mean ± SD
CBT-I (n = 9)b 
Mean ± SD
Wellness education (n = 9)b 
Mean ± SD
Age (years) 63 ± 10 65 ± 9 60 ± 10
Men/women (n) 19/4 7/2 7/2
FeV1, % predicted 62 ± 18 62 ± 21 59 ± 18
FeV1/FVC 50 ± 10 47 ± 7 53 ± 14
BMI 25 ± 5 27 ± 6 24 ± 3
race (n) 
  African-American 
  Caucasian 
  Other
 
5 
18 
0
 
1 
8 
0
 
4 
5 
0
educationc 
  Less than high school 
  high school 
  some college 
  College
 
2 
5 
8 
7
 
1 
4 
4 
1
 
0 
1 
4 
4
employmentc 
  retired 
  Part-time 
  Full time 
  Unemployed
 
6 
5 
1 
10
 
3 
2 
1 
3
 
1 
2 
0 
6
smoking, pack-years 46 ± 20 48 ± 32 41 ± 8
Psg, apnea/hypopnea index 4 ± 3 5 ± 3 3.5 ± 2
Psg, periodic limb movement arousal index (per hour) 1.0 ± 2 0.47 ± 0.6 1.5 ± 2
Psg, mean saO2 94 ± 2 95 ± 3 94 ± 1
Psg, minimum saO2 86 ± 5 85 ± 5 86 ± 5
excessive daytime sleepiness (epworth sleepiness scale) 9.2 ± 5 8.0 ± 4.3 11 ± 5
Notes: aIncludes all subjects (CBT-I and We, Phases 1 and 2); bincludes subjects randomized to CBT-I or We (Phase 2); cdata missing for one subject.
Abbreviations: BMI, body mass index; CBT-I, cognitive behavioral therapy for insomnia; FeV1/FVC, forced expiratory volume in 1 second/forced vital capacity; Psg, 
programmable sound generator; We, wellness education; sD, standard deviation.
1.00
CBT-I WE
1.50
2.00
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i
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c
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Figure 2 Acceptability of treatments (CBT-I and We).
Abbreviations: CBT-I, cognitive-behavioral therapy for insomnia; We, wellness 
education.
for the CBT-I group (Table 3). For the WE group, although 
not statistically significant, perceived and actigraphic 
WASO, TST, and SE also moved in an improved direction. 
  Dysfunctional Beliefs and Attitudes about Sleep Scale scores 
at the end of the study (n = 23) were significantly associated 
with insomnia severity (r = 0.61, P = 0.002), PSQI global 
sleep quality (r = 0.60, P = 0.002), CRQ-F (r = −0.60, 
P = 0.004), and POMS-F (r = 0.60, P = 0.003).
Descriptive statistics and pre- and postintervention out-
comes for the fatigue, mood, and daytime functioning measures 
are presented in Table 4. Participants reported moderate levels 
of fatigue at baseline. Significant improvement in CRQ-F scores 
after CBT-I (P = 0.005) was noted and this was corroborated 
by a trend in the POMS-F. Of CBT-I and WE participants, 
57% and 46%, respectively, had at least a 1.00 change in 
CRQ-F after the intervention, suggesting clinical significance. 
For the CBT-I group, neither the POMS-A nor POMS-D 
subscales showed statistically significant improvement from 
pre- to   postintervention. However, for the WE group, signifi-
cantly improved scores on the POMS-D subscale were seen 
(P = 0.005). No significant improvements in either group were 
noted from pre- to postintervention for daytime functioning.
Discussion
Results of this study support the feasibility and   acceptability of 
the CBT-I intervention for people with COPD and insomnia. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Descriptive statistics and effect size for sleep outcomes: all CBT-Ia (Phases 1 and 2, n = 14), CBT-Ib (Phase 2, n = 9), 
Web (Phase 2, n = 9)
Variable 
Measure
Preintervention 
Mean ± SD
Postintervention 
Mean ± SD
Within-group difference 
Mean ± SD
P value Within-group 
effect size
Subjective sleep outcomes
Insomnia severity (sII)26,29
  All CBT-I 
  CBT-I 
  We
16.6 ± 4.9 
15.9 ± 5.6 
13.9 ± 4.5
10.6 ± 4.1 
10.7 ± 4.4 
12.4 ± 3.3
−5.9 ± 3.3 
−5.2 ± 3.7 
−1.4 ± 3.7
0.000 
0.003 
0.273
1.79* 
1.40* 
0.38
global sleep quality (PsQI)32,33 (lower is better)
  All CBT-I 
  CBT-I 
  We
11.0 ± 3.6 
10.1 ± 3.7 
7.1 ± 2.4
6.5 ± 3.4 
7.2 ± 3.7 
7.5 ± 2.4
−4.5 ± 4.4 
−2.9 ± 4.2 
0.44 ± 1.9
0.002 
0.068 
0.512
1.02* 
0.69 
0.23
Dysfunctional beliefs and attitudes about sleep (DBAs 30)37,38
  All CBT-I 
  CBT-I 
  We
4.1 ± 1.5 
4.1 ± 1.8 
3.7 ± 0.94
3.1 ± 1.7 
3.2 ± 2.0 
3.4 ± 1.4
−1.0 ±.74 
−0.85 ± 0.80 
−0.32 ± 0.91
0.000 
0.013 
0.317
1.35* 
1.06* 
0.35
Sleep continuity, sleep diary26
sleep latency (min) 
  All CBT-I 
  CBT-I 
  We
32 ± 50 
37 ± 60 
22 ± 18
17 ± 16 
19 ± 19 
23 ± 11
−15 ± 34 
−18 ± 41 
1 ± 9
0.136 
0.219 
0.734
0.44 
0.44 
0.11
Wake after sleep onset (min)
  All CBT-I 
  CBT-I 
  We
70 ± 56 
68 ± 38 
59 ± 63
30 ± 17 
34 ± 19 
38 ± 23
−39 ± 57 
−34 ± 41 
−21 ± 53
0.030 
0.037 
0.272
0.68* 
0.83* 
0.40
Total sleep time (min) 
  All CBT-I 
  CBT-I 
  We
365 ± 82 
361 ± 68 
382 ± 114
404 ± 55 
408 ± 57 
448 ± 114
40 ± 76 
47 ± 67 
66 ± 106
0.080 
0.071 
0.099
0.53 
0.70 
0.62
number of awakenings 
  All CBT-I 
  CBT-I 
  We
2.2 ± 1 
2.6 ± 1 
2.1 ± 1
1.9 ± 0.91 
2.1 ± 0.88 
2.0 ± 1.4
−0.35 ± 0.90 
−0.44 ± 0.99 
−0.09 ± 1.0
0.184 
0.223 
0.248
0.39 
0.44 
0.09
Sleep efficiency (%) 
  All CBT-I 
  CBT-I 
  We
78 ± 17 
78 ± 15 
82 ± 13
89 ± 6 
88 ± 7 
87 ± 5
11 ± 14 
11 ± 12 
4 ± 13
0.017 
0.031 
0.177
0.78* 
0.92* 
0.31
Sleep continuity, actigraphy
Wake after sleep onset (min) 
  All CBT-I 
  CBT-I 
  We
98 ± 60 
103 ± 59 
117 ± 72
64 ± 32 
68 ± 39 
105 ± 56
−33 ± 64 
−35 ± 71 
−13 ± 65
0.070 
0.180 
0.578
0.52 
0.49 
0.20
Total sleep time (min) 
  All CBT-I 
  CBT-I 
  We
365 ± 82 
361 ± 68 
268 ± 90
405 ± 55 
408 ± 57 
292 ± 65
40 ± 76 
47 ± 67 
25 ± 51
0.080 
0.071 
0.183
0.53 
0.70 
0.49
number of awakenings 
  All CBT-I 
  CBT-I 
  We
40 ± 13 
45 ± 15 
33 ± 10
36 ± 12 
35 ± 13 
33 ± 9
−4.3 ± 15 
−9.0 ± 14 
0.35 ± 8
0.292 
0.070 
0.908
0.29 
0.64 
0.04
Sleep efficiency (%) 
  All CBT-I 
  CBT-I 
  We
72 ± 10 
71 ± 11 
61 ± 17
79 ± 9 
78 ± 11 
64 ± 15
7 ± 10 
7 ± 12 
3 ± 13
0.028 
0.120 
0.427
0.70* 
0.58 
0.23
Notes: aFive CBT-I participants in Phase 1 and 9 participants in Phase 2; brandomized to CBT-I or We; *P , 0.05. 
Abbreviations: CBT-I, cognitive behavioral therapy for insomnia; We, wellness education; DBs 30, Dysfunctional Beliefs and Attitudes about sleep scale; sII, sleep 
Impairment Index; PsQI, Pittsburgh sleep Quality Index; sD, standard deviation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 4 Descriptive statistics and effect size for fatigue, mood, and daytime function
Variable 
measure
Preintervention 
Mean ± SD
Postintervention 
Mean ± SD
Within-group difference 
Mean ± SD
P value Within-group   
effect size
Fatigue
CrQ-F39–42 (lower indicates greater fatigue)
  All CBT-I 
  CBT-I 
  Web
3.9 ± 1.1 
3.7 ± 1.3 
3.5 ± 1.2
4.6 ± 0.95 
4.5 ± 1.0 
4.1 ± 1.2
−0.75 ± 0.84 
−0.75 ± 0.87 
−0.54 ± 1.3
0.005 
0.033 
0.313
0.89* 
0.86* 
0.41
POMs-F43,44
  All CBT-I 
  CBT-I 
  We
8.6 ± 5.7 
10.3 ± 6.3 
10.3 ± 6.3
6.6 ± 5.5 
7.7 ± 5.6 
10.0 ± 8.1
−2.0 ± 4.5 
−2.7 ± 4.5 
−0.33 ± 3.3
0.122 
0.115 
0.771
0.44 
0.60 
0.10
Mood
POMs-A43,44 
  All CBT-I 
  CBT-I 
  We 
7.9 ± 6.9 
9.4 ± 8.2 
8.6 ± 3.7 
6.6 ± 4.6 
7.7 ± 5.2 
6.1 ± 3.4 
−1.4 ± 4.7 
−1.6 ± 5.3 
−2.4 ± 3.8 
0.296 
0.376 
0.091 
0.30 
0.30 
0.63 
POMs-D43,44
  All CBT-I 
  CBT-I 
  We
7.6 ± 8.9 
9.9 ± 10.3 
10.4 ± 8.2
4.8 ± 7.1 
6.6 ± 8.4 
5.8 ± 6.8
−2.8 ± 5.3 
−3.3 ± 6.0 
−4.6 ± 3.5
0.072 
0.133 
0.005
0.53 
0.55 
1.31*
Daytime functioning
FPI45,46 total score 
  All CBT-I 
  CBT-I 
  We
2.2 ± 0.40 
2.3 ± 0.33 
2.2 ± 0.44
2.3 ± 0.29 
2.3 ± 0.27 
2.2 ± 0.47
0.09 ± 0.24 
0.01 ± 0.15 
−0.03 ± 0.16
0.218 
0.778 
0.607
0.37 
0.10 
0.19
Notes: All CBT-I (n = 14), CBT-Ia (n = 9), Wea (n = 9). arandomized to CBT-I or We; bn = 7 due to missing data; *P , 0.05. 
Abbreviations: CBT-I, cognitive behavioral therapy for insomnia; We, wellness education; CrQ-F, Chronic respiratory Disease Questionnaire Fatigue scale; POMs, 
Profile of Mood States; POMS-F, Profile of Mood States fatigue-inertia subscale; POMS-A, Profile of Mood States tension-anxiety subscale; POMS-D, Profile of Mood States 
depression-dejection subscale; FPI, Functional Performance Inventory; sD, standard deviation.
The data show that the recruiting and retaining of participants 
was successful, with high attendance rates. The study did, 
however, demonstrate a high percentage of primary sleep 
disorders (sleep apnea, periodic limb movements) that lim-
ited recruitment. It remains to be determined whether the 
40% of subjects excluded for primary sleep disorders would 
benefit from CBT-I after successful treatment of their other 
sleep disorder.
In testing the effects of the CBT-I on sleep-related outcomes, 
the present findings are supportive of CBT-I being an effective 
intervention for people with COPD for improving perceived 
sleep quality and objective sleep indicators. Untreated, study 
participants with COPD reported moderate levels of insomnia29 
and lower sleep quality at baseline compared with data in the 
literature about healthy older adults.52 This is indicative of their 
need for treatment to improve sleep quality. The effect trends 
for indicators of improved sleep are similar to those found 
in previous studies of CBT-I in older adults with comorbid 
insomnia.15,16,21,22,52 It was evident that the comparison interven-
tion of WE had positive effects but many of the within-group 
effect sizes associated with the CBT-I intervention were at least 
twice as large as those in the WE group.
When compared with meta-analytic norms6 of perceived 
sleep continuity outcomes after CBT-I in people with 
  insomnia, the change scores of the present study were compa-
rable, but CBT-I participants had somewhat lower effect sizes 
(sleep latency = 0.44 vs 1.05, wake after sleep onset = 0.83 vs 
1.03, number of awakenings = 0.44 vs 0.83, subjective sleep 
quality = 1.02 vs 1.44) except for total sleep time, which was 
higher (0.70 vs 0.46). There are several possible reasons for 
this. The sample of participants with COPD comprised 80% 
men, which may account for some of the difference in the 
effect sizes. Another is that the difference in outcome was 
related to features of COPD that were present throughout 
the intervention period. Evidence supporting this is that the 
effect sizes had greater accordance with previous studies of 
CBT-I in people with insomnia comorbid with other medi-
cal illnesses.13,17,21,22 CBT-I study participants had relatively 
low sleep latency (32 minutes) at baseline, which could have 
affected the sleep latency outcome. Finally, the sleep restric-
tion provided in this study was probably not as aggressive as 
in some studies of CBT-I. Evidence supporting this is that the 
total sleep time after the intervention discussed was higher 
than would be expected after a maximal sleep restriction.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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With regard to the effect of CBT-I on fatigue, higher 
POMS-F scores were seen at baseline compared with lev-
els reported in the literature about healthy older adults.44,54 
  Baseline CRQ-F scores were comparable with those previ-
ously found in elderly adults with COPD.55 Fatigue scores 
were reduced following the CBT-I intervention as indicated 
by the CRQ-F, although this was not evident in the POMS-F 
subscale. The observation of reduced fatigue is in accordance 
with Espie and colleagues, who reported significant reduc-
tions in fatigue after CBT-I in cancer patients.16 Clearly, issues 
of fatigue measurement are complex.
In the CBT-I group, no intervention effects on mood 
state or daytime functions were evident, in accordance with 
previous studies of older adults with insomnia in the context 
of other chronic illnesses.15,21,22,53 An unexpected finding was 
that, compared with the CBT-I group, the WE group had 
improved anxiety and depression with much larger within-
group effect sizes. A possible reason is that the components 
of the WE addressed a number of major areas of interest 
to those with COPD, such as managing exacerbations and 
breathing techniques for minimizing breathlessness. WE 
could have increased perceived self-efficacy in achieving 
control over their COPD and consequently or separately 
improved mood. This observation is consistent with the 
findings of Kunik and colleagues, who reported improved 
anxiety and expression after eight sessions of WE in people 
with COPD.56
Limitations of this study include small sample size, lack 
of postintervention objective COPD disease severity mea-
sures, and lack of complete long-term follow-up. However, 
follow-up data on five participants in CBT-I were collected, 
3 months or longer postintervention. It was found that the 
insomnia severity within group difference (mean [SD]) pre-
post CBT-I was virtually unchanged (0.000[3]), suggesting 
that results were lasting. Despite the limitations, this study 
provides valuable preliminary information about CBT-I for 
people with COPD and insomnia.
Conclusion
This study was not powered to test for statistically signifi-
cant differences between the interventions, but the sleep and 
fatigue outcome data indicate a large within-group effect 
size, which could potentially translate into improved patient 
outcomes. These results must be interpreted with caution 
because of the small sample size. However, the data suggest 
that CBT-I is feasible as an option for insomnia in COPD and 
that it may have effects similar to those found in its use with 
older adults with insomnia comorbid with other illnesses. 
A larger, adequately powered study will be necessary to 
address the efficacy of CBT-I for people with COPD.
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